Pfizer's Setback in Obesity Space

This chapter discusses Pfizer's setback in the obesity space due to the high rate of side effects caused by their drug Dining Glipron. Over 70% of trial participants reported nausea, nearly half experienced vomiting, and a quarter experienced diarrhea. Although the drug did deliver weight loss of up to 13%, it fell slightly below expectations. Pfizer plans to continue working on a once daily formulation of the pill to address these issues and expects data on it in the first half of next year.